Health Ministry introduces new drug for MDR TB
Advertisement
New Delhi: Concerned over the rising number of multi-drug resistant (MDR) tuberculosis cases in the country, the health ministry will introduce a new drug in a "controlled manner".
As a pilot, 400 courses of Delamanid will be rolled out in five to six states as part of the conditional access programme under the Revised National TB Control Program (RNTCP).
According to a senior health ministry official, Delamanid which is in its phase 3 clinical trials, has been given approval by a technical group on tuberculosis in the ministry.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.